Literature DB >> 20124169

Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09.

Anthony L Zietman1, Kyounghwa Bae, Jerry D Slater, William U Shipley, Jason A Efstathiou, John J Coen, David A Bush, Margie Lunt, Daphna Y Spiegel, Rafi Skowronski, B Rodney Jabola, Carl J Rossi.   

Abstract

PURPOSE To test the hypothesis that increasing radiation dose delivered to men with early-stage prostate cancer improves clinical outcomes. PATIENTS AND METHODS Men with T1b-T2b prostate cancer and prostate-specific antigen </= 15 ng/mL were randomly assigned to a total dose of either 70.2 Gray equivalents (GyE; conventional) or 79.2 GyE (high). No patient received androgen suppression therapy with radiation. Local failure (LF), biochemical failure (BF), and overall survival (OS) were outcomes. Results A total of 393 men were randomly assigned, and median follow-up was 8.9 years. Men receiving high-dose radiation therapy were significantly less likely to have LF, with a hazard ratio of 0.57. The 10-year American Society for Therapeutic Radiology and Oncology BF rates were 32.4% for conventional-dose and 16.7% for high-dose radiation therapy (P < .0001). This difference held when only those with low-risk disease (n = 227; 58% of total) were examined: 28.2% for conventional and 7.1% for high dose (P < .0001). There was a strong trend in the same direction for the intermediate-risk patients (n = 144; 37% of total; 42.1% v 30.4%, P = .06). Eleven percent of patients subsequently required androgen deprivation for recurrence after conventional dose compared with 6% after high dose (P = .047). There remains no difference in OS rates between the treatment arms (78.4% v 83.4%; P = .41). Two percent of patients in both arms experienced late grade >/= 3 genitourinary toxicity, and 1% of patients in the high-dose arm experienced late grade >/= 3 GI toxicity. CONCLUSION This randomized controlled trial shows superior long-term cancer control for men with localized prostate cancer receiving high-dose versus conventional-dose radiation. This was achieved without an increase in grade >/= 3 late urinary or rectal morbidity.

Entities:  

Mesh:

Year:  2010        PMID: 20124169      PMCID: PMC2834463          DOI: 10.1200/JCO.2009.25.8475

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  20 in total

1.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

Authors:  Mack Roach; Gerald Hanks; Howard Thames; Paul Schellhammer; William U Shipley; Gerald H Sokol; Howard Sandler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-07-15       Impact factor: 7.038

2.  Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer.

Authors:  Deborah A Kuban; Susan L Tucker; Lei Dong; George Starkschall; Eugene H Huang; M Rex Cheung; Andrew K Lee; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-08-31       Impact factor: 7.038

3.  Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel.

Authors: 
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-03-15       Impact factor: 7.038

4.  Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer.

Authors:  B G Gardner; A L Zietman; W U Shipley; U E Skowronski; P McManus
Journal:  J Urol       Date:  2002-01       Impact factor: 7.450

5.  Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: correlation with original histological grade and current prostate specific antigen levels.

Authors:  T C Dugan; W U Shipley; R H Young; L J Verhey; A F Althausen; N M Heney; P L McManus; E H Abraham
Journal:  J Urol       Date:  1991-11       Impact factor: 7.450

6.  Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

Authors:  Anthony L Zietman; Michelle L DeSilvio; Jerry D Slater; Carl J Rossi; Daniel W Miller; Judith A Adams; William U Shipley
Journal:  JAMA       Date:  2005-09-14       Impact factor: 56.272

7.  Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma.

Authors:  J M Crook; Y A Bahadur; S J Robertson; G A Perry; B A Esche
Journal:  Cancer       Date:  1997-01-01       Impact factor: 6.860

8.  The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer.

Authors:  F A Vicini; L L Kestin; A A Martinez
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-10-01       Impact factor: 7.038

9.  Conformal proton therapy for prostate carcinoma.

Authors:  J D Slater; L T Yonemoto; C J Rossi; N J Reyes-Molyneux; D A Bush; J E Antoine; L N Loredo; R W Schulte; S L Teichman; J M Slater
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-09-01       Impact factor: 7.038

10.  Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial.

Authors:  David P Dearnaley; Matthew R Sydes; John D Graham; Edwin G Aird; David Bottomley; Richard A Cowan; Robert A Huddart; Chakiath C Jose; John Hl Matthews; Jeremy Millar; A Rollo Moore; Rachel C Morgan; J Martin Russell; Christopher D Scrase; Richard J Stephens; Isabel Syndikus; Mahesh K B Parmar
Journal:  Lancet Oncol       Date:  2007-06       Impact factor: 41.316

View more
  243 in total

Review 1.  Clinical evidence of particle beam therapy (proton).

Authors:  Takashi Ogino
Journal:  Int J Clin Oncol       Date:  2012-03-17       Impact factor: 3.402

2.  Radiation therapy in prostate cancer: a risk-adapted strategy.

Authors:  A J Hayden; C Catton; T Pickles
Journal:  Curr Oncol       Date:  2010-09       Impact factor: 3.677

3.  Androgen deprivation therapy for prostate cancer-review of indications in 2010.

Authors:  H Quon; D A Loblaw
Journal:  Curr Oncol       Date:  2010-09       Impact factor: 3.677

4.  Prostate cancer: Patient-reported functional outcomes with radiation therapy.

Authors:  Jeffrey S Montgomery
Journal:  Nat Rev Urol       Date:  2010-10       Impact factor: 14.432

5.  Radiation therapy to the primary tumor in locally advanced prostate cancer is not "closing the barn door after the horse has bolted".

Authors:  Nicholas G Zaorsky; Mark A Hallman; Marc C Smaldone
Journal:  Ann Transl Med       Date:  2015-10

Review 6.  Retreatment for prostate cancer with stereotactic body radiation therapy (SBRT): Feasible or foolhardy?

Authors:  Stefano Arcangeli; Linda Agolli; Vittorio Donato
Journal:  Rep Pract Oncol Radiother       Date:  2014-09-10

7.  [Translational uroradio-oncology].

Authors:  S E Combs; J Debus
Journal:  Urologe A       Date:  2013-09       Impact factor: 0.639

8.  Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.

Authors:  Jeff M Michalski; Jennifer Moughan; James Purdy; Walter Bosch; Deborah W Bruner; Jean-Paul Bahary; Harold Lau; Marie Duclos; Matthew Parliament; Gerard Morton; Daniel Hamstra; Michael Seider; Michael I Lock; Malti Patel; Hiram Gay; Eric Vigneault; Kathryn Winter; Howard Sandler
Journal:  JAMA Oncol       Date:  2018-06-14       Impact factor: 31.777

Review 9.  Systematic review of hypofractionated radiation therapy for prostate cancer.

Authors:  Nicholas G Zaorsky; Nitin Ohri; Timothy N Showalter; Adam P Dicker; Robert B Den
Journal:  Cancer Treat Rev       Date:  2013-03-01       Impact factor: 12.111

Review 10.  Hypofractionated radiotherapy for localized prostate cancer.

Authors:  Stefan Höcht; Daniel M Aebersold; Clemens Albrecht; Dirk Böhmer; Michael Flentje; Ute Ganswindt; Tobias Hölscher; Thomas Martin; Felix Sedlmayer; Frederik Wenz; Daniel Zips; Thomas Wiegel
Journal:  Strahlenther Onkol       Date:  2016-09-14       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.